U.S. Markets open in 3 hrs 46 mins
  • S&P Futures

    4,620.25
    +54.00 (+1.18%)
     
  • Dow Futures

    34,752.00
    +295.00 (+0.86%)
     
  • Nasdaq Futures

    16,373.00
    +222.50 (+1.38%)
     
  • Russell 2000 Futures

    2,242.30
    +45.00 (+2.05%)
     
  • Crude Oil

    69.08
    +2.90 (+4.38%)
     
  • Gold

    1,787.30
    +10.80 (+0.61%)
     
  • Silver

    22.92
    +0.10 (+0.46%)
     
  • EUR/USD

    1.1325
    -0.0014 (-0.1246%)
     
  • 10-Yr Bond

    1.4430
    0.0000 (0.00%)
     
  • Vix

    23.83
    +6.72 (+39.28%)
     
  • GBP/USD

    1.3306
    +0.0004 (+0.0333%)
     
  • USD/JPY

    113.4650
    +0.2850 (+0.2518%)
     
  • BTC-USD

    57,047.89
    +140.40 (+0.25%)
     
  • CMC Crypto 200

    1,468.46
    +0.53 (+0.04%)
     
  • FTSE 100

    7,154.63
    +95.18 (+1.35%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Richard J. Rubino, Chief Financial Officer, will present in a fireside discussion at the Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 8:00 a.m. Eastern Time. Mr. Rubino will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005024/en/

Contacts

Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com